Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA CEO Tauzin Takes Over Jan. 3: PR Focus Begins At The Top

This article was originally published in The Tan Sheet

Executive Summary

PhRMA's new management team under CEO Billy Tauzin will place a high priority on communications and partnerships with other stakeholders in healthcare policy debates

You may also be interested in...



Energy & Commerce chair

Rep. Joe Barton (R-Tex.) could be named to fill chairman seat at the House Energy & Commerce Committee as early as week of Feb. 9, staffers say. Barton is lead candidate to replace Billy Tauzin (R-La.), who steps down as chair effective Feb. 16. Tauzin is rumored to be the top choice to head the Pharmaceutical Research & Manufacturers of America. Under Tauzin, committee held hearings on dietary supplement safety, with a focus on ephedra, in 2003. As chair of the Commerce/Oversight & Investigations Subcommittee in mid to late 1990s, Barton examined a number of health-related issues...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS097654

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel